Fondazione

Brescia, Italy

Fondazione

Brescia, Italy
SEARCH FILTERS
Time filter
Source Type

CORAL GABLES, Fla., May 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that an abstract highlighting the results of an investigator-sponsored Phase 2b study of Firdapse® (amifampridine phosphate) in the treatment of MuSK antibody positive myasthenia gravis (MuSK-MG) has been accepted for a scientific poster presentation at the 13th International Conference on Myasthenia Gravis and Related Disorders to be held on May 15-17, 2017 in New York. “The current pilot study with MuSK-MG patients showed measurable evidence of benefit in all the assessed outcome measures, despite the small sample size.  We feel these results are a strong signal that amifampridine phosphate can be a safe, effective treatment for the difficult to manage symptoms of MuSK-MG.  An expanded trial will seek to confirm the results presented in Dr. Mantegazza’s abstract,” said Gary Ingenito, M.D., Ph.D., Catalyst’s Chief Medical Officer. This study was conducted by a team of researchers led by Renato Mantegazza, MD and Silvia Bonanno, M.D., Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico “Carlo Besta” in Milan, Italy, a major referral center for MuSK-MG patients. The poster presentation details are as follows: Title: “MuSK MG Patients Showed a Positive Response to Amifampridine Phosphate in a Randomized, Placebo-Controlled, Crossover Study” Poster Session: Day 1 Poster Session at Marriott Downtown, 85 West St., New York, NY 10280 Session Date/Time: May 15, 2017 from 6:00 to 8:30 PM Authors: Silvia Bonanno, M.D., Barbara Pasanisi, M.D., Carlo Antozzi, M.D., Lorenzo Maggi, M.D., Francesca Andreetta, Ph.D., Ornella Simoncini, MSc., and Renato Mantegazza, M.D. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether Catalyst can successfully design and complete a registration trial evaluating Firdapse for the treatment of MuSK-MG that is acceptable to the FDA, whether any such trial for the treatment of MuSK-MG that is acceptable to the FDA will be successful, whether Catalyst can obtain the funding required to conduct such a trial, and those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.


CORAL GABLES, Fla., May 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that an abstract highlighting the results of an investigator-sponsored Phase 2b study of Firdapse® (amifampridine phosphate) in the treatment of MuSK antibody positive myasthenia gravis (MuSK-MG) has been accepted for a scientific poster presentation at the 13th International Conference on Myasthenia Gravis and Related Disorders to be held on May 15-17, 2017 in New York. “The current pilot study with MuSK-MG patients showed measurable evidence of benefit in all the assessed outcome measures, despite the small sample size.  We feel these results are a strong signal that amifampridine phosphate can be a safe, effective treatment for the difficult to manage symptoms of MuSK-MG.  An expanded trial will seek to confirm the results presented in Dr. Mantegazza’s abstract,” said Gary Ingenito, M.D., Ph.D., Catalyst’s Chief Medical Officer. This study was conducted by a team of researchers led by Renato Mantegazza, MD and Silvia Bonanno, M.D., Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico “Carlo Besta” in Milan, Italy, a major referral center for MuSK-MG patients. The poster presentation details are as follows: Title: “MuSK MG Patients Showed a Positive Response to Amifampridine Phosphate in a Randomized, Placebo-Controlled, Crossover Study” Poster Session: Day 1 Poster Session at Marriott Downtown, 85 West St., New York, NY 10280 Session Date/Time: May 15, 2017 from 6:00 to 8:30 PM Authors: Silvia Bonanno, M.D., Barbara Pasanisi, M.D., Carlo Antozzi, M.D., Lorenzo Maggi, M.D., Francesca Andreetta, Ph.D., Ornella Simoncini, MSc., and Renato Mantegazza, M.D. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether Catalyst can successfully design and complete a registration trial evaluating Firdapse for the treatment of MuSK-MG that is acceptable to the FDA, whether any such trial for the treatment of MuSK-MG that is acceptable to the FDA will be successful, whether Catalyst can obtain the funding required to conduct such a trial, and those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.


CORAL GABLES, Fla., May 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that an abstract highlighting the results of an investigator-sponsored Phase 2b study of Firdapse® (amifampridine phosphate) in the treatment of MuSK antibody positive myasthenia gravis (MuSK-MG) has been accepted for a scientific poster presentation at the 13th International Conference on Myasthenia Gravis and Related Disorders to be held on May 15-17, 2017 in New York. “The current pilot study with MuSK-MG patients showed measurable evidence of benefit in all the assessed outcome measures, despite the small sample size.  We feel these results are a strong signal that amifampridine phosphate can be a safe, effective treatment for the difficult to manage symptoms of MuSK-MG.  An expanded trial will seek to confirm the results presented in Dr. Mantegazza’s abstract,” said Gary Ingenito, M.D., Ph.D., Catalyst’s Chief Medical Officer. This study was conducted by a team of researchers led by Renato Mantegazza, MD and Silvia Bonanno, M.D., Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico “Carlo Besta” in Milan, Italy, a major referral center for MuSK-MG patients. The poster presentation details are as follows: Title: “MuSK MG Patients Showed a Positive Response to Amifampridine Phosphate in a Randomized, Placebo-Controlled, Crossover Study” Poster Session: Day 1 Poster Session at Marriott Downtown, 85 West St., New York, NY 10280 Session Date/Time: May 15, 2017 from 6:00 to 8:30 PM Authors: Silvia Bonanno, M.D., Barbara Pasanisi, M.D., Carlo Antozzi, M.D., Lorenzo Maggi, M.D., Francesca Andreetta, Ph.D., Ornella Simoncini, MSc., and Renato Mantegazza, M.D. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether Catalyst can successfully design and complete a registration trial evaluating Firdapse for the treatment of MuSK-MG that is acceptable to the FDA, whether any such trial for the treatment of MuSK-MG that is acceptable to the FDA will be successful, whether Catalyst can obtain the funding required to conduct such a trial, and those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.


News Article | May 10, 2017
Site: www.businessoffashion.com

LONDON, United Kingdom — Over the past few years, Moncler has consistently outperformed the luxury sector. While overall sales of personal luxury goods remained flat last year, Moncler's revenue grew by 18 percent in 2016, hitting €1 billion on the strength of its down jackets. However the company’s dominance in the luxury outerwear market may be over, argues Luca Solca, head of luxury goods at Exane BNP Paribas, who has downgraded the company from a “neutral” rating to “underperform.” Solca believes Moncler’s growth may slow at least in the medium term, as other players in the sector begin to challenge its market share. “Moncler is trying to tackle the medium-term threats posed by dependence on a narrow product range, the risk of fading brand momentum, and the need to sustain high margins,” said Solca in an analyst note. “It would be naive to expect any brand to sustain growth above the market average forever. In addition, Moncler should cease to be a top performer on earnings before interest and taxes growth, as some self-help stories in the sector are poised to deliver more. This could trigger further de-rating or underperformance in the soft luxury sector.” Certainly, Moncler’s store network contributes to those high margins, and will continue to expand. The company aims to open 10 to 15 stores a year in new markets like Dubai, Melbourne and Stockholm, as well as expanding some existing locations in Milan and Hong Kong. And while the product range remains narrow (goose down coats account for 75 to 80 percent of sales), the brand has seen some success with diversification into categories like knitwear, shoes and soft accessories. “The other categories are growing and they are growing fast,” chief executive Remo Ruffini told BoF in March. “With knitwear, we see a lot of interesting numbers and I think in the future, we can have the possibility to do the same with soft accessories. People ask for gloves, hats, scarves. I think it could be a very interesting number for us in the near future.” For now, Solca believes the fundamentals in the market for luxury down jackets remain positive. Between 2009 and 2016, the sector grew from €500 million to €2 billion at a compounded annual growth rate of 22 percent, according to a report from the Boston Consulting Group and Fondazione Altagamma. “We believe that the luxury down jacket segment is in a sweet spot,” said Solca. “Two-thirds of ‘true luxury consumers’ increasingly favour casualwear over formalwear, with those who are older facing wardrobe saturation and those who are younger finding casualwear more appealing.” But Moncler may become a victim of its own success, as it has attracted new players to the market like Mr & Mrs Italy, Moose Knuckles and Perfect Moment to name a few, that threaten to challenge its dominance in the luxury outerwear sector. “Moncler has many areas of excellence,” acknowledged Solca, listing its profitability, retail productivity and communication as attractive. “With retail equivalent sales more than double those of its nearest rival, Moncler is the undisputed leader in an attractive niche where high growth is supported by the luxury casualisation wave. “[But] Moncler’s high growth rates and profitability have attracted newcomers as well as existing brands operating in contiguous business segments,” he added. “While still dominant, Moncler’s market share is declining.” With €1 Billion in Sales, Can Moncler Continue to Grow? Far From Slopes, Skiwear Heats Up


CORAL GABLES, Fla., May 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that an abstract highlighting the results of an investigator-sponsored Phase 2b study of Firdapse® (amifampridine phosphate) in the treatment of MuSK antibody positive myasthenia gravis (MuSK-MG) has been accepted for a scientific poster presentation at the 13th International Conference on Myasthenia Gravis and Related Disorders to be held on May 15-17, 2017 in New York. “The current pilot study with MuSK-MG patients showed measurable evidence of benefit in all the assessed outcome measures, despite the small sample size.  We feel these results are a strong signal that amifampridine phosphate can be a safe, effective treatment for the difficult to manage symptoms of MuSK-MG.  An expanded trial will seek to confirm the results presented in Dr. Mantegazza’s abstract,” said Gary Ingenito, M.D., Ph.D., Catalyst’s Chief Medical Officer. This study was conducted by a team of researchers led by Renato Mantegazza, MD and Silvia Bonanno, M.D., Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico “Carlo Besta” in Milan, Italy, a major referral center for MuSK-MG patients. The poster presentation details are as follows: Title: “MuSK MG Patients Showed a Positive Response to Amifampridine Phosphate in a Randomized, Placebo-Controlled, Crossover Study” Poster Session: Day 1 Poster Session at Marriott Downtown, 85 West St., New York, NY 10280 Session Date/Time: May 15, 2017 from 6:00 to 8:30 PM Authors: Silvia Bonanno, M.D., Barbara Pasanisi, M.D., Carlo Antozzi, M.D., Lorenzo Maggi, M.D., Francesca Andreetta, Ph.D., Ornella Simoncini, MSc., and Renato Mantegazza, M.D. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether Catalyst can successfully design and complete a registration trial evaluating Firdapse for the treatment of MuSK-MG that is acceptable to the FDA, whether any such trial for the treatment of MuSK-MG that is acceptable to the FDA will be successful, whether Catalyst can obtain the funding required to conduct such a trial, and those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.


CORAL GABLES, Fla., May 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that an abstract highlighting the results of an investigator-sponsored Phase 2b study of Firdapse® (amifampridine phosphate) in the treatment of MuSK antibody positive myasthenia gravis (MuSK-MG) has been accepted for a scientific poster presentation at the 13th International Conference on Myasthenia Gravis and Related Disorders to be held on May 15-17, 2017 in New York. “The current pilot study with MuSK-MG patients showed measurable evidence of benefit in all the assessed outcome measures, despite the small sample size.  We feel these results are a strong signal that amifampridine phosphate can be a safe, effective treatment for the difficult to manage symptoms of MuSK-MG.  An expanded trial will seek to confirm the results presented in Dr. Mantegazza’s abstract,” said Gary Ingenito, M.D., Ph.D., Catalyst’s Chief Medical Officer. This study was conducted by a team of researchers led by Renato Mantegazza, MD and Silvia Bonanno, M.D., Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico “Carlo Besta” in Milan, Italy, a major referral center for MuSK-MG patients. The poster presentation details are as follows: Title: “MuSK MG Patients Showed a Positive Response to Amifampridine Phosphate in a Randomized, Placebo-Controlled, Crossover Study” Poster Session: Day 1 Poster Session at Marriott Downtown, 85 West St., New York, NY 10280 Session Date/Time: May 15, 2017 from 6:00 to 8:30 PM Authors: Silvia Bonanno, M.D., Barbara Pasanisi, M.D., Carlo Antozzi, M.D., Lorenzo Maggi, M.D., Francesca Andreetta, Ph.D., Ornella Simoncini, MSc., and Renato Mantegazza, M.D. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether Catalyst can successfully design and complete a registration trial evaluating Firdapse for the treatment of MuSK-MG that is acceptable to the FDA, whether any such trial for the treatment of MuSK-MG that is acceptable to the FDA will be successful, whether Catalyst can obtain the funding required to conduct such a trial, and those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.


CORAL GABLES, Fla., May 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that an abstract highlighting the results of an investigator-sponsored Phase 2b study of Firdapse® (amifampridine phosphate) in the treatment of MuSK antibody positive myasthenia gravis (MuSK-MG) has been accepted for a scientific poster presentation at the 13th International Conference on Myasthenia Gravis and Related Disorders to be held on May 15-17, 2017 in New York. “The current pilot study with MuSK-MG patients showed measurable evidence of benefit in all the assessed outcome measures, despite the small sample size.  We feel these results are a strong signal that amifampridine phosphate can be a safe, effective treatment for the difficult to manage symptoms of MuSK-MG.  An expanded trial will seek to confirm the results presented in Dr. Mantegazza’s abstract,” said Gary Ingenito, M.D., Ph.D., Catalyst’s Chief Medical Officer. This study was conducted by a team of researchers led by Renato Mantegazza, MD and Silvia Bonanno, M.D., Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico “Carlo Besta” in Milan, Italy, a major referral center for MuSK-MG patients. The poster presentation details are as follows: Title: “MuSK MG Patients Showed a Positive Response to Amifampridine Phosphate in a Randomized, Placebo-Controlled, Crossover Study” Poster Session: Day 1 Poster Session at Marriott Downtown, 85 West St., New York, NY 10280 Session Date/Time: May 15, 2017 from 6:00 to 8:30 PM Authors: Silvia Bonanno, M.D., Barbara Pasanisi, M.D., Carlo Antozzi, M.D., Lorenzo Maggi, M.D., Francesca Andreetta, Ph.D., Ornella Simoncini, MSc., and Renato Mantegazza, M.D. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether Catalyst can successfully design and complete a registration trial evaluating Firdapse for the treatment of MuSK-MG that is acceptable to the FDA, whether any such trial for the treatment of MuSK-MG that is acceptable to the FDA will be successful, whether Catalyst can obtain the funding required to conduct such a trial, and those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.


ATLANTA--(BUSINESS WIRE)--Nel 2016 la Fondazione Coca-Cola e The Coca-Cola Company hanno donato complessivamente più 106 milioni di dollari a oltre 230 organizzazioni. Tali contributi andranno direttamente a favore della collettività in più di 200 Paesi e territori, ove approssimativamente il 97 per cento delle sovvenzioni è stato destinato alle cause cui The Coca-Cola Company attribuisce priorità, ossia donne, risorse idriche e benessere collettivo.


News Article | February 20, 2017
Site: phys.org

Michelangelo Pistoletto is acknowledged as one of the founding fathers of the Italian Arte Povera contemporary art movement and is widely regarded as one of the most influential artists of his generation. The Arte Povera movement grew throughout Italy between the end of the 1960s and the beginning of the 1970s. Literally meaning 'poor art', this vivid art movement is characterised by its use of found and unconventional materials. Pistoletto's work mainly deals with the subject of the unification of art and everyday life, and his ongoing 'Third Paradise' project, conceived in 2003, envisions a third 'realm' that merges natural and artificial worlds and a society living in harmony with nature. Pistoletto began his cooperation with ESA for the development of the official mission patch of Paolo Nespoli's VITA mission, which includes the artist's symbol of his Third Paradise concept in the artwork designed by ESA for ASI, the Italian space agency. A natural continuation of this cooperation is the brand-new 'Spac3' app, which will allow users to select and combine Paolo's images from space with their own photos. Developed by ESA and ASI in close cooperation with RAM radioartemobile and Cittadellarte-Fondazione Pistoletto, the app will be launched at the same time as Paolo's launch into space later this year. As a user of this Spac3 app, you'll be able to receive the photos taken by Paolo during his mission and then you'll be invited to generate a new image based on six different themes inspired by the UN's sustainable development goals. These themes are: Life on land; Good health and wellbeing; Industry, innovation and infrastructure; Climate action; Life below water, and Sustainable cities and communities. Focusing on one of those themes, you'll create a unique and personal image that is an original combination of Paolo's space image and your Earth-based one. Your combination will be shaped into the Third Paradise symbol and then published as part of a larger interactive artwork by Pistoletto. The VITA mission, provided by ASI through a barter agreement with NASA, will be Paolo's third spaceflight when he is launched later this year as flight engineer on Expeditions 52/53. Paolo's first spaceflight was the two-week Esperia mission on the Space Shuttle STS-120 in 2007. He returned to the Station in 2010 for ESA's 160-day MagISStra mission as part of Expeditions 26/27. Explore further: Vita: next Space Station mission name and logo


News Article | February 15, 2017
Site: www.businesswire.com

IRVINE, California--(BUSINESS WIRE)--Il Dottor Javier Dávila Torres ha annunciato, insieme a 11 funzionari del Messico, al Vertice mondiale sulla sicurezza dei pazienti, la scienza e la tecnologia organizzato dalla Fondazione del Movimento per la sicurezza dei pazienti (Patient Safety Movement Foundation, PSMF) che 25 ospedali hanno sottoscritto un impegno per l'implementazione di processi tesi ad eliminare i decessi di pazienti prevenibili. Inoltre, l’Accademia di chirurgia del Messico, la Federazione degli anestesiologi e il Collegio dei professionisti in materia di qualità delle cure sanitarie dell'Occidente, di Guadalajara e Jalisco sono entrati a far parte della Fondazione come “partner impegnati” condividenti la missione della PSMF.

Loading Fondazione collaborators
Loading Fondazione collaborators